Panbela Therapeutics, Inc. Completes Enrollment in Its Phase 1b Trial Investigating SBP-101 Combination Therapy for First-Line Metastatic Pancreatic Cancer

Panbela Therapeutics, Inc., formerly Sun Biopharma, a UF startup and clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has completed patient enrollment in its Phase 1 trial evaluating the safety and tolerability of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA). 

“We are pleased to have completed enrollment in our Phase 1b trial and expect to announce data in the first half of next year,” commented Jennifer Simpson, PhD., M.S.N., C.R.N.P., president and chief executive officer.  “Completing enrollment for SBP-101 marks an important milestone in our quest to bring new therapeutic options to patients with pancreatic cancer, which is an orphan disease and an area of unmet medical need.”

Learn more about Panbela Therapeutics, Inc. Completes Enrollment in Its Phase 1b Trial Investigating SBP-101 Combination Therapy for First-Line Metastatic Pancreatic Cancer.